D
Dale G. Renlund
Researcher at University of Utah
Publications - 200
Citations - 11055
Dale G. Renlund is an academic researcher from University of Utah. The author has contributed to research in topics: Transplantation & Heart transplantation. The author has an hindex of 56, co-authored 200 publications receiving 10629 citations. Previous affiliations of Dale G. Renlund include Primary Children's Hospital & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
The Intermountain Risk Score (including the red cell distribution width) predicts heart failure and other morbidity endpoints.
Benjamin D. Horne,Benjamin D. Horne,Heidi T May,Abdallah G. Kfoury,Dale G. Renlund,Dale G. Renlund,Joseph B. Muhlestein,Joseph B. Muhlestein,Donald L Lappe,Donald L Lappe,Kismet Rasmusson,T. Jared Bunch,T. Jared Bunch,John F. Carlquist,John F. Carlquist,Tami L Bair,Kurt R. Jensen,Brianna S. Ronnow,Jeffrey L. Anderson,Jeffrey L. Anderson +19 more
TL;DR: The complete blood count and basic metabolic profile are common, low‐cost blood tests, which have previously been used to create and validate the Intermountain Risk Score (IMRS) for mortality prediction.
Journal ArticleDOI
Age-associated decline in cardiac allograft rejection
Dale G. Renlund,Dale G. Renlund,Edward M. Gilbert,Edward M. Gilbert,John B. O'Connell,John B. O'Connell,Kent W. Jones,Kent W. Jones,Burton Na,Burton Na,Donald B. Doty,Donald B. Doty,Shreekant V. Karwande,Shreekant V. Karwande,Charles W. DeWitt,Charles W. DeWitt,Ronald L. Menlove,Ronald L. Menlove,Colette M. Herrick,Colette M. Herrick,Michael R. Bristow,Michael R. Bristow +21 more
TL;DR: In this article, the influence of age on cardiac allograft rejection was studied in 57 consecutive recipients and younger age was found to add significantly as a predictor of rejection in a multivariate analysis that controlled for sex, immunosuppressive agents, cause of heart failure, and pretransplantation lymphocyte cross-match status (r = 0.64, p less than 0.05).
Journal ArticleDOI
Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study.
Jon A. Kobashigawa,Dale G. Renlund,Gino Gerosa,Luis Almenar,Howard J. Eisen,Anne Keogh,Hans B. Lehmkuhl,Ugolino Livi,Heather J. Ross,Javier Segovia,Nizar Yonan +10 more
TL;DR: These 6- and 12-month results show that EC-MPS is therapeutically similar to MMF in de novo heart transplant recipients and has a comparable safety profile.
Journal Article
Successful treatment of a cardiac angiosarcoma with combined modality therapy.
TL;DR: It is proposed that a more aggressive management of patients with difficult conditions with primary angiosarcoma of the heart is warranted.
Journal Article
Immunosuppressive therapy, management, and outcome of heart transplant recipients during pregnancy.
Lynne E. Wagoner,David O. Taylor,Olsen Sl,Price Gd,L. G. Rasmussen,C. B. Larsen,James R. Scott,Dale G. Renlund +7 more
TL;DR: Of the 29 children born of heart transplant recipients who became pregnant, no fetal anomalies or neonatal deaths occurred, and Prematurity and low birth weight were the most common complications.